132 related articles for article (PubMed ID: 33040318)
1. The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network.
Moradi MT; Fallahi H; Rahimi Z
Mol Biol Rep; 2020 Oct; 47(10):7685-7697. PubMed ID: 33040318
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma.
Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S
Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018
[TBL] [Abstract][Full Text] [Related]
3. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer.
Ma Y; Bu D; Long J; Chai W; Dong J
J Cell Physiol; 2019 Mar; 234(3):2880-2894. PubMed ID: 30203615
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer.
Tarighi M; Khalaj-Kondori M; Hosseinzadeh A; Abtin M
Breast Dis; 2021; 40(2):63-68. PubMed ID: 33554879
[TBL] [Abstract][Full Text] [Related]
5. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
[TBL] [Abstract][Full Text] [Related]
6. DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker.
Khorshidi H; Azari I; Oskooei VK; Taheri M; Ghafouri-Fard S
Breast Dis; 2019; 38(1):25-30. PubMed ID: 30594914
[TBL] [Abstract][Full Text] [Related]
7. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
8. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
[TBL] [Abstract][Full Text] [Related]
9. Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT.
Yue Z; Shusheng J; Hongtao S; Shu Z; Lan H; Qingyuan Z; Shaoqiang C; Yuanxi H
Aging (Albany NY); 2020 Jul; 12(14):14754-14774. PubMed ID: 32716908
[TBL] [Abstract][Full Text] [Related]
10. DSCAM-AS1 regulates the G
Sun W; Li AQ; Zhou P; Jiang YZ; Jin X; Liu YR; Guo YJ; Yang WT; Shao ZM; Xu XE
Cancer Med; 2018 Dec; 7(12):6137-6146. PubMed ID: 30430768
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
12. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA DSCAM-AS1 is associated with poor clinical prognosis and contributes to melanoma development by sponging miR-136.
Huang YL; Xu Q; Wang X
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2888-2897. PubMed ID: 31002140
[TBL] [Abstract][Full Text] [Related]
15. LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer.
Hu C
Mini Rev Med Chem; 2023; 23(5):530-536. PubMed ID: 35996247
[TBL] [Abstract][Full Text] [Related]
16. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A.
Liao J; Xie N
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1087-1092. PubMed ID: 30779076
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4.
Li Y; Hao J; Jiang YM; Liu Y; Zhang SH
Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4143-4148. PubMed ID: 31173284
[TBL] [Abstract][Full Text] [Related]
19. Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer.
Müller V; Oliveira-Ferrer L; Steinbach B; Pantel K; Schwarzenbach H
Mol Oncol; 2019 May; 13(5):1137-1149. PubMed ID: 30803129
[TBL] [Abstract][Full Text] [Related]
20. DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3'-End Usage.
Elhasnaoui J; Miano V; Ferrero G; Doria E; Leon AE; Fabricio ASC; Annaratone L; Castellano I; Sapino A; De Bortoli M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32503257
[No Abstract] [Full Text] [Related]
[Next] [New Search]
